Allt inom Q1
Nanexa publishes interim report for January-March 2024
NEX-22 clinical trial preparations ongoing and Novo Nordisk collaboration progressing well
Nanexa publishes interim report for January – March 2023
Positive pre-clinical data with NEX-22, NEX-20 phase I continues and good progress in partner projects